RareDiseasesNews.net

Rare diseases Xagena

Xagena Mappa
Xagena Newsletter
OncologiaMedica.net
Medical Meeting

Search results for "Polyneuropathy"

The aim of a study was to determine whether the clinical characteristics and electrodiagnostic classification of nerve injury, and response to treatment differed in patients diagnosed with chronic inf ...


The involvement of optic and auditory pathways has rarely been studied in demyelinating polyneuropathies. A cohort of patients with acquired and genetic demyelinating neuropathy has been studied. T ...


Although various modalities of treatment of chronic inflammatory demyelinating polyradiculopathy ( CIDP ) there are not any treatment protocol agreed. Researchers have retrospectively evaluated the ...


The prospective, multicenter, single-arm, open-label phase III PRIMA trial has evaluated the efficacy and safety of Privigen ( 10% liquid human intravenous immunoglobulin [ IVIG ], stabilized with L-p ...


Although various modalities of treatment of chronic inflammatory demyelinating polyradiculopathy ( CIDP ) there are not any treatment protocol agreed. Researchers have retrospectively evaluated the ...


Only 70-80% of patients with chronic inflammatory demyelinating polyneuropathy ( CIDP ) respond satisfactorily to the established first-line immunomodulatory treatments. Autologous haematopoietic st ...


HELIOS-A phase 3 study of Vutrisiran, an investigational RNAi therapeutic in development for the treatment of transthyretin-mediated ( ATTR ) amyloidosis, met its primary and both secondary endpoints ...


Full positive results from the HELIOS-A phase 3 study of Vutrisiran, an investigational RNAi therapeutic in development for the treatment of transthyretin-mediated ( ATTR ) amyloidosis, which met its ...